Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

172 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Inhibition of MDR1 Overcomes Resistance to Brentuximab Vedotin in Hodgkin Lymphoma.
Chen R, Herrera AF, Hou J, Chen L, Wu J, Guo Y, Synold TW, Ngo VN, Puverel S, Mei M, Popplewell L, Yi S, Song JY, Tao S, Wu X, Chan WC, Forman SJ, Kwak LW, Rosen ST, Newman EM. Chen R, et al. Among authors: herrera af. Clin Cancer Res. 2020 Mar 1;26(5):1034-1044. doi: 10.1158/1078-0432.CCR-19-1768. Epub 2019 Dec 6. Clin Cancer Res. 2020. PMID: 31811017 Free PMC article. Clinical Trial.
A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation.
Davids MS, Kim HT, Costello C, Herrera AF, Locke FL, Maegawa RO, Savell A, Mazzeo M, Anderson A, Boardman AP, Weber A, Avigan D, Chen YB, Nikiforow S, Ho VT, Cutler C, Alyea EP, Bachireddy P, Wu CJ, Ritz J, Streicher H, Ball ED, Bashey A, Soiffer RJ, Armand P. Davids MS, et al. Among authors: herrera af. Blood. 2020 Jun 11;135(24):2182-2191. doi: 10.1182/blood.2019004710. Blood. 2020. PMID: 32478814 Free PMC article. Clinical Trial.
Polatuzumab Vedotin for Relapsed/Refractory Aggressive B-cell Lymphoma: A Multicenter Post-marketing Analysis.
Smith SD, Lopedote P, Samara Y, Mei M, Herrera AF, Winter AM, Hill BT, Shadman M, Ujjani C, Lynch RC, Jacobson CA, Kim AI, Caimi P, Milano F, Gopal AK. Smith SD, et al. Among authors: herrera af. Clin Lymphoma Myeloma Leuk. 2021 Mar;21(3):170-175. doi: 10.1016/j.clml.2020.12.013. Epub 2020 Dec 18. Clin Lymphoma Myeloma Leuk. 2021. PMID: 33431309
Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma.
Halwani AS, Panizo C, Isufi I, Herrera AF, Okada CY, Cull EH, Kis B, Chaves JM, Bartlett NL, Ai W, de la Cruz-Merino L, Bryan LJ, Houot R, Linton K, Briones J, Chau I, von Keudell GR, Lu H, Yakovich A, Chen M, Meulen Jh T, Yurasov S, Hsu FJ, Flowers CR. Halwani AS, et al. Among authors: herrera af. Leuk Lymphoma. 2022 Apr;63(4):821-833. doi: 10.1080/10428194.2021.2010057. Epub 2021 Dec 6. Leuk Lymphoma. 2022. PMID: 34865586 Clinical Trial.
PD-1 Blockade After Avelumab in Relapsed/Refractory Classical Hodgkin Lymphoma.
Thiruvengadam SK, Mei MG, Godfrey J, Siddiqi T, Salhotra A, Chen R, Smith E, Popplewell LL, Herrera AF. Thiruvengadam SK, et al. Among authors: herrera af. Clin Lymphoma Myeloma Leuk. 2022 Oct;22(10):e893-e897. doi: 10.1016/j.clml.2022.06.004. Epub 2022 Jun 6. Clin Lymphoma Myeloma Leuk. 2022. PMID: 35778267
Results of a Phase II Trial of Allogeneic Hematopoietic Stem Cell Transplantation Using 90Y-Ibritumomab Tiuxetan (Zevalin) in Combination With Fludarabine and Melphalan in Patients With High-Risk B-Cell Non-Hodgkin's Lymphoma.
Mei M, Palmer J, Tsai NN, Simpson J, O'Hearn J, Stein A, Forman S, Spielberger R, Cai JL, Htut M, Nakamura R, Al Malki MM, Herrera A, Wong J, Nademanee A. Mei M, et al. Clin Lymphoma Myeloma Leuk. 2023 Sep;23(9):e268-e276. doi: 10.1016/j.clml.2023.05.011. Epub 2023 May 23. Clin Lymphoma Myeloma Leuk. 2023. PMID: 37301631 Free PMC article. Clinical Trial.
Flotetuzumab as a salvage immunotherapy in advanced CD123-positive hematological malignancies, a phase 1 pilot study.
Aldoss I, Zhang J, Robbins M, Song J, Al Malki MM, Otoukesh S, Sandhu K, Agrawal V, Herrera AF, Popplewell LL, Ghoda L, Stein A, Marcucci G, Forman S, Pullarkat V. Aldoss I, et al. Among authors: herrera af. Leuk Lymphoma. 2024 Aug;65(8):1127-1135. doi: 10.1080/10428194.2024.2343029. Epub 2024 Apr 17. Leuk Lymphoma. 2024. PMID: 38629176 Clinical Trial.
Brentuximab Vedotin Plus Ibrutinib in Relapsed and Refractory Hodgkin Lymphoma.
Mei M, Tsai NC, Palmer J, Armenian S, Chen R, Rosen S, Forman S, Popplewell L, Kwak L, Martin P, Maddocks K, Bond D, Herrera AF. Mei M, et al. Among authors: herrera af. Clin Lymphoma Myeloma Leuk. 2024 Aug;24(8):537-542. doi: 10.1016/j.clml.2024.03.013. Epub 2024 Apr 10. Clin Lymphoma Myeloma Leuk. 2024. PMID: 38693037 Clinical Trial.
Phase I Trial of Brentuximab Vedotin Plus Cyclosporine in Relapsed/Refractory Hodgkin Lymphoma.
Thiruvengadam SK, Mei MG, Chen L, Puverel S, Chen R, Popplewell LL, Nikolaenko L, Peters L, Armenian S, Kwak LW, Rosen ST, Forman SJ, Herrera AF. Thiruvengadam SK, et al. Among authors: herrera af. Clin Lymphoma Myeloma Leuk. 2024 Oct;24(10):724-731.e1. doi: 10.1016/j.clml.2024.05.017. Epub 2024 Jun 15. Clin Lymphoma Myeloma Leuk. 2024. PMID: 39043499 Clinical Trial.
172 results